Video: Can Adcetris spawn new therapies for relapsed or refractory Hodgkin's lymphoma?

Can a new antibody drug conjugate, ADCETRIS (brentuximab vedotin), be the foundation of new combination therapies for patients with relapsed or refractory Hodgkin's lymphoma? Dr. Joseph Connors, a leader in lymphoma treatment from Vancouver, Canada, discusses the possibilities that could bring new hope to patients with this rare condition. He believes new research could have promising benefits for patients living with the condition today.

More Videos

LymphomaInfo Social